CYBC1

CYBC1 (also called EROS) is an endoplasmic reticulum-resident transmembrane chaperone essential for the biogenesis and stabilization of the phagocyte NADPH oxidase (NOX2) and purinergic receptor complexes, thereby governing reactive oxygen species production and innate immune signaling. EROS directly binds immature gp91phox (NOX2) in the ER, preventing its degradation and facilitating glycosylation and heme incorporation required for assembly of the catalytically competent gp91phox–p22phox heterodimer; a 3.56 Å cryo-EM structure shows EROS holds NOX2 in a protected, FAD-shifted conformation via two antiparallel transmembrane helices, and activation-dependent stimulation dissociates EROS to permit superoxide production (PMID:28351984, PMID:36421765, PMID:38805284). EROS additionally serves as a selective chaperone for purinergic receptors P2X7 and P2X1, transiently associating with P2X7 to promote stable homotrimer formation and enabling downstream inflammasome activation and IL-1β secretion (PMID:31862710, PMID:36421765). Loss-of-function mutations in CYBC1 cause chronic granulomatous disease in humans (PMID:30312704, PMID:30361506).

1. 2017 High

   Establishing that EROS is required for phagocyte NADPH oxidase expression and host defense resolved the long-standing question of whether additional factors beyond known NOX2 subunits were needed for oxidase biogenesis.

   Evidence Eros-knockout mice showed loss of gp91phox/p22phox protein, failed oxidative burst, lethal susceptibility to infection, and impaired NET formation

   PMID:28351984

   Open questions at the time

   • Mechanism by which EROS controls gp91phox/p22phox abundance was not defined
   • Whether EROS acts as a transcriptional regulator or post-translational chaperone was unknown
   • Human relevance not yet demonstrated
2. 2018 High

   Demonstrating that human CYBC1 loss-of-function mutations cause chronic granulomatous disease established EROS as a bona fide disease gene and confirmed conservation of the oxidase-regulatory function from mouse to human.

   Evidence Patient mutation analysis, immunoblotting for gp91phox/p22phox, and oxidative burst assays in EROS-deficient human phagocytes; corroborated by independent Icelandic cohort

   PMID:30312704 PMID:30361506

   Open questions at the time

   • Direct physical interaction between EROS and NOX2 subunits not yet shown
   • Subcellular site of action not established
3. 2019 High

   Identifying EROS as an ER-resident chaperone for P2X7 expanded its functional scope beyond NOX2 and revealed it promotes homotrimeric assembly of a client receptor through transient association.

   Evidence Genome-wide CRISPR screen, ER localization by subcellular fractionation, reciprocal co-immunoprecipitation of EROS–P2X7, and multiple functional readouts (PtdSer exposure, dye uptake, Ca²⁺ flux, IL-1β secretion) in knockout cell lines and primary macrophages

   PMID:31862710

   Open questions at the time

   • Structural basis of EROS–P2X7 interaction unknown
   • Whether EROS chaperones additional client proteins beyond NOX2 and P2X7 was unresolved
4. 2022 High

   Defining the precise step at which EROS acts — binding immature 58 kDa gp91phox to enable glycosylation and heme loading — established its role as an early biogenesis chaperone rather than a late stabilizer, and extended its client repertoire to include P2X1.

   Evidence Co-immunoprecipitation with immature gp91phox, glycosylation/heme-incorporation assays, proteomic interactome by mass spectrometry, P2X1 binding assays, and Eros-KO mouse influenza infection model

   PMID:36421765

   Open questions at the time

   • Atomic-level mechanism of EROS-mediated NOX2 stabilization unknown
   • How EROS is released upon NOX2 maturation was unclear
5. 2024 High

   A cryo-EM structure of the EROS–NOX2–p22phox heterotrimer revealed the structural mechanism: EROS binds NOX2 via transmembrane helices and induces conformational distortions that increase heme–heme distance and shift the FAD site, locking NOX2 in a protected state that is released upon activation.

   Evidence 3.56 Å cryo-EM, site-directed mutagenesis, PMA-induced dissociation assays in transfected COS-7 cells, superoxide production assays, and HL-60 differentiated neutrophil-like cell surface localization

   PMID:38805284

   Open questions at the time

   • Structure of EROS bound to P2X7 or P2X1 clients not determined
   • In vivo dynamics of EROS dissociation during neutrophil activation not characterized
   • Whether EROS re-engages NOX2 after activation is unknown
6. 2024 Medium

   Extending EROS function to vascular endothelial cells showed it regulates NOX2 and RAC1 abundance, ROS-dependent calcium signaling, eNOS activation, and cell migration, broadening its physiological relevance beyond phagocytes.

   Evidence siRNA knockdown and CRISPR KO in HUVECs with ROS assays, Ca²⁺ imaging, senescence assays, eNOS phosphorylation, and quantitative proteomics

   PMID:38805973

   Open questions at the time

   • Endothelial findings from a single laboratory, not independently replicated
   • Whether EROS directly chaperones RAC1 or affects it indirectly through NOX2 is unresolved
   • In vivo vascular phenotype of EROS deficiency not tested

• Key unresolved questions include the structural basis of EROS interaction with P2X7/P2X1 clients, the full client repertoire of EROS as an ER chaperone, the mechanism governing EROS recycling or degradation after client release, and the in vivo relevance of EROS in non-immune cell types such as endothelium.
• No structural data for EROS–P2X7 or EROS–P2X1 complexes
• Comprehensive client profiling via unbiased interactomics not yet performed across tissue types
• Post-dissociation fate of EROS protein is unknown